Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
188 Leser
Artikel bewerten:
(1)

BC Platforms Partners with Blueprint Genetics to Provide Center of Excellence for Data Driven Testing Services in Rare Diseases

ZURICH and BOSTON, Oct. 17, 2019 /PRNewswire/ -- BC Platforms, a world leader in genomic data management and analytics, today announced that it has formed a collaboration with Blueprint Genetics, a leader in the field of clinical genetic testing, to develop new data driven services for hospitals and the life sciences industry.

The collaboration combines Blueprint Genetics' excellence in clinical genetic testing with BC Platforms' high performing data management platform to facilitate the utilization of large amounts of genetic data in day-to-day patient care, clinical studies and industry initiatives such as sponsored testing programs. This all-encompassing approach will be supported by a secure and fully compliant system that maintains privacy while supporting openness and collaboration.

The second element of this project will be the creation of an advanced platform for the provision of genetic data and providing a scalable environment for data storage and analysis. This technology is supported by high-quality, curated data sets and health-related information. Such a wide breadth of organized, harmonized data will support efficient genetic testing results and ultimately improve patient care. Essentially, creating this seamless platform for integrated genetic testing and clinical data applications will serve to enable precision medicine by combining technical expertise and unique approaches to clinical genomics.

Tero Silvola, CEO of BC Platforms, commented on the partnerships, "We are delighted to be working with Blueprint Genetics, who are rapidly establishing themselves as leaders in the clinical genetic testing field for rare diseases. We believe that together we can provide a highly competitive platform and a one-stop shop for genetic testing and data management to help patients suffering from rare inherited diseases."

"I am very excited about this collaboration. Linking our high-quality genetic testing with BC Platforms data management capabilities allows us to improve patient outcomes, reduce operating costs in healthcare organizations and speed up the time-to-discovery," commented Blueprint Genetics' CEO Tommi Lehtonen.

About BC Platforms

BC Platforms is a world leader in providing powerful genomic data management and analysis solutions. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. The company has launched and opened a global network of biobanks, known as BCRQUEST.COM, to provide genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms' vision is to build the world's leading analytics platform for healthcare and industry by 2020, providing access to diverse genomic and clinical data and samples from more than 5 million subjects consolidated from a global network of biobanks.

Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and sales and marketing in London, Boston, and Vancouver. For more information, please visit www.bcplatforms.com or follow us on Twitter @BCPlatforms.

About Blueprint Genetics

Blueprint Genetics is one of the fastest growing genetic testing businesses globally in the field of clinical genetic testing of rare inherited diseases. With a patient centered mindset, the company was founded in 2012 and has since been on a mission to bring world-class genetic knowledge to mainstream healthcare with four guiding principles: innovation, transparency, quality and accessibility. The company is based in Helsinki and Seattle, with a customer base spanning over 70 countries. https://blueprintgenetics.com.

Contact information:

BC Platforms:
Tero Silvola, CEO
tero.silvola@bcplatforms.com

Katja Stout
Scius Communications
katja@sciuscommunications.com

Blueprint Genetics:

Tommi Lehtonen, CEO
tommi.lehtonen@blueprintgenetics.com

Juulia Simonen, Communications manager
juulia.simonen@blueprintgenetics.com

© 2019 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.